

October 27, 2023

To,
THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: INFINIUM

Dear Sir/Madam,

Sub: Outcome of Board Meeting

As per Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and in furtherance to our intimation letter dated October 18, 2023, we hereby inform the stock exchange that the Board of Directors of the company at its meeting held today i.e. **Friday, October 27, 2023** inter-alia decided as under:

1. Considered and approved Standalone unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2023.
2. Considered and approved Consolidated unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2023.
3. Took note of the resignation of Mrs. Vrunda Harishbhai Patel as Company Secretary & Compliance Officer and Chief Financial Officer(CFO) of the company w.e.f. 18th November, 2023.
4. Considered and approved the appointment of Mr. Nilesh Patel as Company Secretary & Compliance Officer and Chief Financial Officer(CFO) of the company w.e.f. 20th November, 2023.
5. Considered and approved Internal audit report for the half year ended September 30, 2023.

Kindly note that the meeting of the Board of Directors of the Company commenced at 11:45 a.m. and concluded at 12:20 p.m.

We request you to kindly take the same on your record.

Thanking You,

Yours Sincerely,

FOR INFINIUM PHARMACHEM LIMITED

PRAVIN BHADABHAI MADHANI
DIRECTOR
DIN: 00370791

ASHOK RAJPARA & CO

Chartered Accountants

Independent Auditor's Review Report on Standalone Unaudited Half Yearly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **INFINIUM PHARMACHEM LIMITED** ('the Company') for the half year ended September 30, 2023 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of interim Financial Information Performed by the Independent Auditor of the Entity's, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial Information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For , ASHOK RAJPARA & CO
CHARTERED ACCOUNTANTS


(ASHOK RAJPARA)
PROPRIETOR
M. No. 100559
FRN No : 153195W
UDIN : 23100559BGWQNB3308

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

Place : SURAT
Date : 27/10/2023

STATEMENT OF STANDALONE ASSETS AND LIABILITIES

PARTICULAR	(Rs. In Lacs)		
	As At 30.09.2023	As At 30.09.2022	As At 31.03.2023
	UnAudited	Audited	Audited
A. ASSETS			
1. NON CURRENT ASSETS			
(a) Property, Plant and Equipment	1580.18	376.85	1558.03
(b) Intangible Assets	0	0.00	0.00
(c) Capital Work in Progress	0	1148.74	0.00
(d) Intangible Assets under development	0	0.00	0.00
(e) Non Current Investments	34.11	34.11	34.11
(f) Deferred Tax assets(Net)	6.63	8.05	5.16
(g) Long term Loans and Advances	31.10	31.13	31.10
(h) Other Non Current Assets	48.07	96.49	13.00
Total Non Current Assets	1700.09	1695.37	1641.39
2. CURRENT ASSETS			
(a) Inventories	1803.21	1605.12	1791.34
(b) Financial Assets			
(i) Current Investments	0.00	0.00	0.00
(ii) Trade Receivable	2704.00	1858.45	1516.02
(iii) Cash and Cash Equivalents	975.94	227.08	331.51
(iv) Other Balance With Banks	0.06	0.12	0.06
(v) Loans and Advances	322.20	458.26	739.16
(vi) Other Asstes	1693.03	196.24	22.33
Total Current Assets	7498.44	4345.26	4400.44
TOTAL ASSETS	9198.53	6040.63	6041.83
B. EQUITY AND LIABILITIES			
1. EQUITY			
(a) Equity Share Capital	1391.61	508.31	508.31
(b) Other Equity	3917.31	1246.54	1661.59
Total Equity	5308.92	1754.85	2169.89
2. LIABILITY			
NON-CURRENT LIABILITIES			
(a) Financial Liabilities	0.00	0.00	0.00
(b) Deferred Tax Liabilities	0.00	0.00	0.00
(c) Other Non Current Liabilities	657.49	1614.71	763.05
Total Non Current Liabilities	657.49	1614.71	763.05
CURRENT LIABILITIES			
(a) Financial Liabilities			
(i) Trade Payables	751.88	955.76	877.82
(1) Total outstanding dues of MSME.	47.45	1.10	20.65
(2) Total outstanding dues Otherthan MSME.	704.43	954.66	857.17
(ii) Other Financial Liabilities	2100.66	860.99	1846.45
(b) Other Current Liabilities	52.69	151.80	0.72
(c) Provisions	119.69	490.92	74.81
(d) Income tax Liabilities	207.20	211.61	309.09
Total Current Liabilities	3232.12	2671.07	3108.89
TOTAL	9198.53	6040.63	6041.83

For, INFINIUM PHARMACHEM LTD

Pravin Madhani
Director
DIN No. : 00370791

Place : Sojitra
Date : 27/10/2023

STATEMENT OF STANDALONE FINANCIAL RESULT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2023

PARTICULARS	(Rs. In Lacs)		
	For the Half Year ended 30st September, 2023	For the Half Year ended 30st September, 2022	For the Year ended 31st March, 2023
	UnAudited	Audited	Audited
INCOME			
Revenue from Operations	5085.24	5820.02	10130.62
Other Income, net	33.76	57.41	134.34
TOTAL INCOME	5119.00	5877.44	10264.96
EXPENSES			
Cost of Matetrial Consumed	3818.16	4534.56	7152.53
Purchases of Traded Goods		0.00	0.00
Changes In Inventories of FG., WIP.	-239.72	-360.45	-96.79
Employee Benefits Expenses	208.57	169.44	366.62
Financial Cost	84.96	111.95	299.65
Deprecaition and Amortization Expenses	114.49	27.29	128.91
Other Expenses	315.30	726.65	1187.56
TOTAL EXPENSES	4301.76	5209.44	9038.47
Profit Before eceptional and extraordinary Items	817.24	668.00	1226.49
Exceptional Items	0.00	0.00	0.00
Profit Before Taxes	817.24	668.00	1226.49
Tax Expenses			
(a) Current Tax	207.20	169.43	309.09
(b) Deferred Tax (Liabilities)/Assets	-1.47	1.31	1.58
(c) Prior Year Tax (Liabilities)/Assets	-1.80	0.00	0.90
Profit (Loss) for the period	613.31	499.87	914.92
Earning Per Share			
Weighted Ave. No. Of Share	139.16	50.83	50.83
(a) Basic	4.41	9.83	18.00
(b) Dilluted	4.41	9.83	18.00

Notes For Standalone Financial Results :


- The above Standalone Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2023 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 27th October, 2023
- The above Standalone Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2023 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Rules, 2014 as amended) and other recongnised accounting practices and policies, as applicable.
- The company had made an initial public issue (SME -IPO) of 18,75,000 equity shares of face vale of Rs. 10/- fully paid up for cash at a price of Rs 135/- per equity share (including share premium of Rs. 125/- per equity share) aggregating to Rs. 2525.72 Lakhs. SME- IPO opened for public on 31st March,2023 and listed on NSE -SME Platform on 17th April, 2023.
- The management is in process of indentifying parties which are covered under MSME, the amount relating to MSME are disclosed to the extent identified.
- The Compnay has only one reported business segment i.e. Chemicals, accordingly segment disclosure is not required as per Ind AS 108.
- Figures for the previous years/periods have been reclassified/ rearranged/regrouped to confirm to clasification of current period, whenever necessary

Place : Sojitra
Date : 27/10/2023

For, INFINIUM PHARMACHEM LTD

Pravin Madhani
Director
DIN No. : 00370791

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2023

Particular	(Rs. In Lacs)		
	For the Half Year ended 30th September, 2023	For the Half Year ended 30th September, 2022	For the Year ended 31st March, 2023
	UnAudited	Audited	Audited
A. Cash Flow from Operating Activities			
Net Profit / (Loss) before Tax	817.24	668.00	1226.49
Adjustments for :			
Depreciation and Amortization	114.49	27.29	128.91
Financial Cost	84.96	111.95	299.65
Interest Received	-0.57	-0.17	-1.34
Other Non Operating income	0	0.00	0.00
Operating Profit before working capital changes	1016.12	807.07	1653.71
Adjustments for (increase)/Decrease in operating assets :			
Trade Receivable	-1187.98	-563.58	-221.15
Inventories	-11.87	-182.41	-368.63
Loans and Advances	416.96	8.12	-272.79
Other Current Assets	-1670.7	-141.35	32.55
Adjustments for increase/(Decrease) in operating liabilities :			
Trade Payable	-125.94	-69.16	-147.10
Other Non Current Liabilities	-105.56	252.33	-599.33
Other Financial Liabilities- Current	254.21	-28.69	956.77
Other Current Liabilities	51.97	136.84	-14.24
Provisions	-57.00	343.77	25.15
Increase / (Decrease) in Non Current Assets			
Cash Generated From Operations	-1419.79	562.94	1044.94
Direct Tax	205.4	169.43	309.99
Indirect Tax			
Net Cash From Operating Activities (A)	-1625.19	393.51	734.94
B. Cash Flow from Investing Activities			
Purchase of Tangible Fixed Assets (Gross)	-136.64	-330.63	-464.68
Purchase of Intangible Fixed Assets (Gross)	0	0.00	0.00
Increase / (Decrease) in Non Current Investment	0	-7.65	-7.65
Long term Loans and Advances	0	-19.72	-19.68
Other Non Current Assets	-35.07	148.99	232.48
Other Non Current Investments	0	0.00	0.00
Interest Received	0.57	0.17	1.34
Other Non Operating income	0	0.00	0.00
Net Cash used in Investing Activities (B)	-171.14	-208.85	-258.20
C. Cash Flow from Financing Activities			
Proceeds from Issuing share	2525.72	0.00	0.00
Interest / Financial Charges Paid	-84.96	-111.95	-299.65
Net Cash used in Financing Activities (c)	2440.76	-111.95	-299.65
Net Increase / (Decrease) in cash and cash equivalents (A+B+C)	644.43	72.71	177.09
Cash and cash equivalents at the beginning of the year	331.57	154.48	154.48
Cash and cash equivalents at the end of the year	976.00	227.19	331.58
Place : Sojitra Date : 27/10/2023 For, INFINIUM PHARMACHEM LTD  Pravin Madhani Director DIN No. : 00370791			

ASHOK RAJPARA & CO

Chartered Accountants

Independent Auditor's Review Report on Consolidated Unaudited Half Yearly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **INFINIUM PHARMACHEM LIMITED** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary constitute "the Group") for the half year ended September 30, 2023 ('the Statement'), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
 2. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of interim Financial Information Performed by the Independent Auditor of the Entity's, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial Information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The statement includes the results of the following entities:
 - i. Shanghai Tajilin Industrial Co Ltd. - China
 - ii. Infinium Green Energy Private Limited - India
 5. The consolidated Unaudited Financial Results include the interim financial information of one subsidiary which has not been reviewed by us and whose interim financial information reflects total revenue of Rs. 993.68 Lacs, total net profit after tax of Rs. 15.86 Lacs for the half year ended September 30, 2023. The subsidiary has been consolidated based on its management certified accounts.

Our conclusion on the Statement is not modified in respect of the above matter.

ASHOK RAJPARA & CO

Chartered Accountants

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, ASHOK RAJPARA & CO
CHARTERED ACCOUNTANTS



(ASHOK RAJPARA)
PROPRIETOR
M. No. 100559
FRN No : 153195W
UDIN : 23100559BGWQNC5753

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS


Place : SURAT

Date : 27/10/2023

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

PARTICULARS	(Rs. In Lacs)		
	As At 30th September,2023	As At 30th September,2022	As At 31st March,2023
	Unaudited	Audited	Audited
A. ASSETS			
I. NON CURRENT ASSETS			
(a) Property, Plant and Equipment	1894.39	418.18	1880.64
(b) Intangible Assets	0.00	0.00	0.00
(c) Capital Work in Progress	0.00	1148.74	0.00
(d) Intangible Assets under development	0.00	0.00	0.00
(e) Non Current Investments	0.00	0.00	0.00
(f) Deferred Tax assets(Net)	11.05	8.05	5.16
(g) Long term Loans and Advances	34.51	31.13	31.10
(h) Other Assets	48.07	96.49	13.00
Total Non Current Assets	1988.02	1702.60	1929.90
2. CURRENT ASSETS			
(a) Inventories	1919.18	1626.32	1971.72
(b) Financial Assets			
(i) Current Investments	0.00	0.00	0.00
(ii) Trade Receivable	2865.48	2364.20	1543.23
(iii) Cash and Cash Equivalents	1276.41	482.78	597.95
(iv) Other Balance With Banks	0.06	0.12	0.06
(v) Loans and Advances	256.99	458.44	679.79
(vi) Other Asstes	1889.34	441.25	338.56
Total Current Assets	8207.46	5373.11	5131.31
TOTAL ASSETS	10195.48	7075.71	7061.22
B. EQUITY AND LIABILITIES			
1. EQUITY			
(a) Equity Share Capital	1391.61	508.31	508.31
(b) Other Equity	4000.70	1347.46	1747.83
(c) Non Controlling Interest	131.35	137.00	122.07
Total Equity	5523.66	1992.77	2378.20
2. LIABILITY			
NON-CURRENT LIABILITIES			
(a) Financial Liabilities	0.00	0.00	0.00
(b) Deferred Tax Liabilities	0.00	0.00	0.00
(c) Other Non Current Liabilities	900.54	1614.71	1006.11
Total Non Current Liabilities	900.54	1614.71	1006.11
CURRENT LIABILITIES			
(a) Financial Liabilities			
(i) Trade Payables	1204.93	1166.08	682.77
(ii) Other Financial Liabilities	2173.34	860.99	1917.88
(b) Other Current Liabilities	52.69	738.63	682.56
(c) Provisions	123.81	490.92	84.61
(d) Income tax Liabilities	216.51	211.61	309.09
Total Current Liabilities	3771.28	3468.22	3676.91
TOTAL	10195.48	7075.71	7061.22
Place : Sojitra Date : 27/10/2023 For, INFINIUM PHARMACHEM LTD  Pravin Madhani Director DIN No. : 00370791			

STATEMENT OF CONSOLIDATED FINANCIAL RESULT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2023

PARTICULARS	(Rs. In Lacs)		
	For the half year ended On 30th September,2023	For the half year ended On 30th September,2022	For the year ended On 31st March,2023
	Unaudited	Audited	Audited
INCOME			
Revenue from Operations	6148.19	7927.59	11422.49
Other Income, net	33.80	57.80	135.16
TOTAL INCOME	6181.99	7985.39	11557.64
EXPENSES			
Cost of Matetrial Consumed	3843.23	4534.56	7152.53
Purchases of Traded Goods	824.03	1738.18	864.44
Changes In Inventories of FG., WIP.	-196.04	-168.24	40.14
Employee Benefits Expenses	217.25	237.86	537.11
Financial Cost	106.37	113.31	310.48
Deprecaition and Amortization Expenses	124.78	29.72	133.88
Other Expenses	433.04	731.76	1223.76
TOTAL EXPENSES	5352.66	7217.13	10262.34
Profit Before Exceptional & Extraordinary Items	829.33	768.26	1295.30
Exceptional Items	0.00	0.00	0.00
Profit Before Taxes	829.33	768.26	1295.30
Tax Expenses	0.00	0.00	0.00
(a) Current Tax	208.88	169.43	311.09
(b) Deffered Tax (Liabilities)/Assets	-5.89	1.31	1.58
(c) Prior Year Tax (Liabilities)/Assets	-1.80	0.00	0.90
Profit after tax for the year	628.14	600.14	981.73
Less : Non Controlling Interest	7.27	49.13	32.74
Profit (Loss) for the period	620.87	551.01	948.99
Earing per equity share			
Weighted Ave. No. Of Share	139.16	50.83	50.83
(a) Basic	4.46	10.84	18.67
(b) Dilluted	4.46	10.84	18.67
Notes For Consolidated Financial Results :			
1. The above Consolidated Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2023 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 27th October, 2023			
2. The above Consolidated Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2023 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Rules, 2014 as amended) and other recongnised accounting practices and policies, as applicable.			
3. Following subsidiary company has been considered in the preparation of consolidated financial statements for the year ended on 30th September, 2023			
Name of the entity		Country Of Incorporation	% Of Holding
Shanghai Tajilin Industrial Co. Limited		China	51%
Infinium Green Energy Private Limited		India	51%
4. The company had made an initial public issue (SME -IPO) of 18,75,000 equity shares of face vale of Rs. 10/- fully paid up for cash at a price of Rs 135/- per equity share (including share premium of Rs. 125/- per equity share) aggregating to Rs. 2525.72 Lakhs. SME- IPO opened for public on 31st March,2023 and listed on NSE -SME Platform on 17th April, 2023.			
5. In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company			
For, INFINIUM PHARMACHEM LTD  Pravin Madhani Director DIN No. : 00370791			
Place : Sojitra Date : 27/10/2023			

CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2023

Particular	(Rs. In Lacs)		
	For the Half Year ended 30th September, 2023	For the Half Year ended 30th September, 2022	For the Year ended 31st March, 2023
	Unaudited	Audited	Audited
A. Cash Flow from Operating Activities			
Net Profit / (Loss) before Tax	829.33	768.26	1295.30
Adjustments for :			
Depreciation and Amortization	124.78	29.72	133.88
Financial Cost	106.37	113.31	310.48
Interest Received	-0.57	-0.56	-1.96
Other Adjustment non cash items -currency fluctuation reserve	-10.40	-5.46	-3.08
Non Controlling Interest	-7.27	-49.13	-32.74
Other Non Operating income			
Operating Profit before working capital changes	1,042.24	856.14	1,701.88
Adjustments for (increase)/Decrease in operating assets :			
Trade Receivable	-1,322.25	-825.02	-4.04
Inventories	52.54	9.80	-335.60
Loans and Advances	422.80	34.58	-186.86
Other Current Assets	-1,550.78	-286.23	-183.55
Adjustments for increase/(Decrease) in operating liabilities :			
Trade Payable	522.16	-15.60	-498.91
Other Non Current Liabilities	-105.57	252.33	-356.27
Other Financial Liabilities- Current	255.46	-28.69	1028.19
Other Current Liabilities	-629.87	26.91	-29.16
Provisions	-53.38	340.19	31.37
Increase / (Decrease) in Non Current Assets			
Cash Generated From Operations	-1,366.65	364.31	1,167.04
Direct Tax	207.08	169.43	311.99
Indirect Tax	0.00	0.00	0.00
Net Cash From Operating Activities (A)	-1,573.73	194.88	855.05
B. Cash Flow from Investing Activities			
Purchase of Tangible Fixed Assets (Gross)	-138.53	-328.74	-746.62
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00	0.00
Increase / (Decrease) in Non Current Assets	0.00	0.00	0.00
Non controlling Interest (BS)	9.28	55.07	40.14
Long term Loans and Advances	-3.41	-19.72	-19.68
Other Non Current Assets	-35.07	148.99	232.48
Interest Received	0.57	0.56	1.96
Other Non Operating income	0.00	0.00	0.00
Net Cash used in Investing Activities (B)	-167.16	-143.84	-491.73
C. Cash Flow from Financing Activities			
Proceeds from Issuing share	2,525.72	0.00	0.00
Interest /Financial Charges Paid	-106.37	-113.31	-310.48
Net Cash used in Financing Activities (C)	2,419.35	-113.31	-310.48
Net Increase / (Decrease) in cash and cash equivalents	678.46	-62.27	52.85
Cash and cash equivalents at the beginning of the year	598.01	545.16	545.16
Cash and cash equivalents at the end of the year	1,276.47	482.89	598.01

For, INFINIUM PHARMACHEM LTD


Pravin Madhani
Director

DIN No. : 00370791

Place : Sojitra
Date : 27/10/2023